Astex Pharmaceuticals Pipeline Data Presentations at AACR

DUBLIN, Calif., April 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of thirteen abstracts covering internal and partner funded pipeline product data for poster or oral presentation at the American Association for Cancer Research (AACR) Annual Meeting April 6 to 10, 2013 in Washington, DC.

"AACR will be a foundational meeting for presenting significant data supporting our clinical programs," said James S.J. Manuso, PhD, chairman and chief executive officer. "Additional data presentations are anticipated for future meetings. Preliminary SGI-110 phase 2 data are expected to be presented at ASH."

SGI-110, a novel hypomethylating agent, will be highlighted in six presentations, including an oral mini-symposia presentation on ovarian cancer chemosensitization, as well as poster presentations on its immunomodulatory activity and its activity in lung cancer:

- **In vivo Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent, in Hematologic Malignancies**
  Abstract 680, Sunday Apr 7, 1:00 - 5:00 pm ET, poster presentation

- **SGI-110 and Entinostat Therapy Reduces Lung Tumor Burden and Reprograms the Epigenome**
  Abstract 679, Sunday, Apr 7, 1:00 — 5:00 pm ET, poster presentation

- **The Novel, Small Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer**
  Abstract 4623, Tuesday, Apr 9, 4:05 - 4:20 pm ET, oral presentation

AT13387, an HSP90 inhibitor, will be presented in a poster session reporting preclinical data in sensitive and resistant prostate cancer tumor models:

- **In vitro and In vivo Anti-Tumor Activity of the Next Generation HSP90 Inhibitor, AT13387, in Both Hormone-Sensitive and Castration-Resistant Prostate Cancer Models**
  Abstract 2433, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation

Two of the four partner funded programs in our portfolio will have data supporting ongoing clinical development:

- **AZD5363**, a PKB/Akt inhibitor:
  **Results of Two Phase I Multicenter Trials of AZD5363, an Inhibitor of AKT1, 2 and 3: Biomarker and Early Clinical Evaluation in Western and Japanese Patients with Advanced Solid Tumors**
  Abstract LB-66, Sunday, Apr 7, 3:30 - 3:50 pm ET, oral presentation

- **LEE011**, a CDK4/6 inhibitor:
  **CDK4/CDK6 Inhibition is Potently Active in a Definable Subset of Human Neuroblastomas**
  Abstract 2744, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation

Additional poster references may be found on the AACR 2013 Annual Meeting website, and select posters will be made available for viewing on the company’s website [www.astx.com](http://www.astx.com) following the respective presentations.

**About Astex Pharmaceuticals**

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on
oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.


CONTACT: Timothy L. Enns

Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns@astx.com

Alan Roemer
The Trout Group
Managing Director
Tel:  +1 (646) 378-2945
E-mail: aroemer@troutgroup.com

Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel:  +1 (925) 560-2845
E-mail: susanna.chau@astx.com